MarginsXMarginsX
Home › Markets › Health Care › CRBU

Caribou Biosciences Inc. (CRBU)

CRBU trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.3528
-2.51% on the day
Market cap
$38.1M
Nano cap
Revenue · 2025
$11.2M
+11.7% on 2024
Net income · 2025
-$148.1M
-1327.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1619856/000161985626000008/0001619856-26-000008-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCRBU on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2021
SEC CIK0001619856
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$11.2M
Net income-$148.1M
Operating income-$148.3M
Net margin-1327.4%
Operating margin-1329.4%
Revenue growth+11.7%
Cash$12.4M
Total assets$175.4M
P/E (computed)Net income was not positive
P/S (computed)3.4×

Warning signs

Cash runway
3.4 months
$26.1M cash at September 30, 2026
Share count, 1 year
+15.6%
2025-11-03 to 2026-11-02 · +22.2% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$34K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$26.1M cash; operating cash flow -$23.3M a quarter.Report 2026-09-30
Shares outstanding108,036,729 (2026-11-02); 93,468,038 a year earlier; 88,431,136 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, San Francisco, California, United StatesPCAOB Form AP 2026-03-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $34K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.6M-$26.6M-$22.5M$26.1MNo debt tags$9.4M10-Q 2026-11-05
Q2 2026
2026-06-30
$1.5M-$24.3M-$22.8M$26.2MNo debt tags$10.0M10-Q 2026-08-13
Q1 2026
2026-03-31
$2.4M-$25.1M-$27.0M$12.1MNo debt tags$11.2M10-Q 2026-05-07
Q4 2025
2025-12-31
$3.9M-$26.5M-$20.8M$12.4MNo debt tags$11.2M10-K 2026-03-05
Q3 2025
2025-09-30
$2.2M-$27.5M-$25.2M$11.1MNo debt tags$9.3M10-Q 2026-11-05
Q2 2025
2025-06-30
$2.7M-$54.1M-$28.3M$25.2MNo debt tags$9.1M10-Q 2026-08-13
Q1 2025
2025-03-31
$2.4M-$40.0M-$36.7M$29.4MNo debt tags$9.9M10-Q 2026-05-07
Q4 2024
2024-12-31
$2.1M-$35.5M-$35.5M$16.3MNo debt tags$10.0M10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32025-05-08
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-06-05

Source: SEC EDGAR submissions feed, 326 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-19.4%
1 month-23.0%
3 months-77.5%
Year to date-77.2%
1 year-81.8%
From 52-week high-85.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
TILInstil Bio Inc.$5.75-5.43%$39.0M
EXOZeXoZymes Inc.$3.99+4.18%$37.1M
ELUTElutia Inc.$0.8229+0.35%$36.5M
IMAImageneBio Inc.$3.20-7.78%$39.9M
KLRSKalaris Therapeutics Inc.$1.46-7.30%$34.8M
LONALeonaBio Inc.$3.23-6.92%$30.4M
INKTMiNK Therapeutics Inc.$9.35+0.11%$48.0M
INMBINmune Bio Inc.$0.9464-9.87%$29.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier